Agilis Robotics launches groundbreaking advancements

Agilis Robotics launches groundbreaking advancements in Endoluminal surgery

Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robotic instruments that offer exceptional dexterity even in the most challenging anatomies. This achievement empowers surgeons to perform intricate tissue resection procedures with precision and ease, directly within natural orifices. Uniquely, the system integrates seamlessly with standard endoscopes used by hospitals and clinics, including colonoscopes and cystoscopes, leveraging existing endoscopic expertise, flattening the learning curve, and improving cost-effectiveness. The robotic instruments offer unprecedented possibilities across endoluminal surgery, spanning the upper and lower gastrointestinal (GI) tract, urinary tract, throat, and gynaecology.

The system consists of a primary cart, a compact control console, and disposable robotic arms which ensure performance and sterility. The cost of the system will be less than 20% of conventional robotic systems on the market, resulting in lower upfront investment and higher gross profits for medical institutions. The demand for endoluminal surgeries is surging worldwide, driven by increasing cancer screening and detection of early-stage tumours. With more than 3.5 million new GI cancer cases and 690k bladder cancer cases per year globally, Agilis Robotics is strategically positioned to capture the underserved endoluminal surgery market, allowing patients to receive effective early-stage treatment with reduced procedure time and recurrence rates.

Agilis Robotics is a spin-off from The University of Hong Kong and has secured more than HKD 90 million in funding from private investors. The funds are being utilized for further development and preparation for clinical trials. The company has completed six live animal studies with their clinical partners in Hong Kong and Shenzhen, demonstrating promising results for the system's accuracy, safety, and efficacy. First-in-human trials are targeted for the first half of 2024. The company is actively preparing for Food and Drug Administration (FDA) and National Medical Products Administration (NMPA) regulatory submissions, which mark a significant milestone towards commercialization.

The company's CFO, Hui Ka-Ming, with extensive experience in investing and pre-profit biotech companies, highlights the success of "Chapter 18A" listed companies in the HKEX, despite their relative immaturity compared to Agilis Robotics. Furthermore, Agilis Robotics understands the importance of cost-effectiveness, marketability, and market potential, ensuring a successful venture for investors and hospitals.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!